+ 86 (1812) 4514114 info@phcoker.com

Paheʻeʻo Avanafil (330784-47-9)

Hoʻohana ʻia ka paukū Avanafil e mālama i nā kāne i loaʻa ka hana (ka mea i kapa ʻia ʻo ka pelekikena pelekane). Na Avanafil i hui pū me …… ..


Kūlana: I ka Production Production
Mokuna: 25kg / Drum
nona iho: 1290kg / ka mahina

Description

ʻO ka'ōmoleʻo Avanafil (330784-47-9)

ʻO ka uila Avanafil (330784-47-9) Hōʻike

Raw Avanafil powder is a PDE5 inhibitor approved for dysfunction(ED: impotence; inability to get or keep an erection in men). Raw Avanafil powder acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. It works by increasing blood flow to the penis during sexual stimulation. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of Raw Avanafil powder is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30–45 minutes.About two-thirds of the participants were able to engage in sexual activity within 15 minutes.

Paheʻeʻo Avanafil (330784-47-9) Snāʻike

Product Name Pālaʻiʻo Avanafil
Hawaiian Name 330784-47-9;STENDRA; (s)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790; TA-1790
Brand Name ʻO Stendra lāuaʻo Spedra
Kōpana Drug PDE5 hoʻolālā
Kāleka CAS 330784-47-9
InChIKey WEAJZXNPAWBCOA-INIZCTEOSA-N
hakakino F'Oula C23H26ClN7O3
hakakino Wʻewalu 483.95
Monoisotopic Mass 483.179 g / mole
Hoʻolaha Pʻo kaʻaila 150-152 ° C
Fkū hou Pʻo kaʻaila ʻAʻoheʻikepili i loaʻa
ʻO ka Halifa-Ola Mean mean-half-life = 5.36 - 10.66 hola
Keʻano ʻO ka pauma
Solakino DMSO, Methanol
Ska hoʻokele Tka mahana E kūʻai i 4 ° C
noi A phosphodiesterase (PDE5) inhibitor, used to treat dysfunction.

ʻO ka uila Avanafil (330784-47-9) Hōʻike

Avanafil is used to treat dysfunction (ED: impotence; inability to get or keep an erection in men). Avanafil powder is in a class of medications called phosphodiesterase (PDE) inhibitors. It works by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Avanafil powder does not cure dysfunction or increase sexual desire. Avanafil does not prevent pregnancy or the spread of sexually transmitted diseases such as human immunodeficiency virus (HIV).

ʻO kaʻeha Avanafil (330784-47-9) Mechanism of Action

Avanafil is a selective phosphodiesterase 5 (PDE5) enzyme inhibitor used for the treatment of dysfunction caused by diabetes, age induced oxidative stress or other complications. Avanafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by avanafil enhances function by increasing the amount of cGMP.

Ke hoʻohanaʻiaʻana o ka paonaʻo Avanafil (330784-47-9)

Avanafil powder is used to treat men who have dysfunction (also called sexual impotence).

Hōʻikeʻia ka paona o Avanafil (330784-47-9) Hana

No ka hapanui o nā kānaka,ʻo ka laha hoʻomaka i ka paona avanafil ka 100 mg i kēlā lā i kēia lā e pili ana i nā minuke 30 ma mua o ka hana maʻamau. Ma muli o ke kūpono o ka pane a iʻole nā ​​hopenaʻaoʻao, hiki ke hoʻonuiʻia ka hōʻailona i ka 200 mg a i emi iho i ka 50 mg i ka lā. ʻO nā kānaka e lawe nei i nā lāʻau e hoʻonui i ke koko o avanafil,ʻaʻole lākou eʻoi aku ma mua o ka nui o ka nui o ka 50 mg i nā hola 24 (Eʻike i nā pilikino).

Nā hua o kaʻepa o'Anaanafil (330784-47-9)

E haʻalele i ka avanafil ae kāhea i kāu kauka inā loaʻa iāʻoe:

▪ nā loli o kaʻike, ka nalowale o kaʻike pōʻino;

▪ ke kani nei i loko o kou mau pepeiao, aiʻole ka loli pepeiao hoʻoloheʻole;

▪ kaʻeha, ka pehuʻana, ka mahana, a me kaʻulaʻula i loko o hoʻokahi aʻelua paha mau wāwae;

▪ ka pōkole o ka hanu, kūpikipiki i loko o kou lima a mau wāwae paha;

▪ he manaʻo hoʻokele, e like paha me kou hikiʻana i waho; aiʻole

▪ ka peni hale e hoʻopiʻi a hoʻomaha paha i nā hola 4 a lōʻihi paha.

Hiki ke komo i nā hopenaʻaoʻao maʻamau:

▪ i ke poʻo;

▪ hoʻohuiʻia (kahi mahana,ʻulaʻula, aʻoluʻolu paha);

▪ nā hōʻailona maʻamau e like me ka ihu iʻole ka ihu, ka puʻu'ā'ī; aiʻole

▪ kaʻeha hou.

NA HALO A E HOOLAHA:

E kūʻai ʻia ana kēia ʻano mea no ka noiʻi noiʻi wale nō. Wahi a ke kūʻai aku. ʻAʻole no ka loiloi kanaka, ʻaʻole lāʻau lapaʻau, manu hoʻāno, a i ʻole e kōkua ʻia nā mea hale.


=

Nāʻike & nā hua'ōlelo huahana

Nā nīnau 9 e nīnau iāʻoe iho ma mua o ka lawe 'ana iā Avanafil

E hoʻomaopopo '

  1. Ryan M Burke, Jeffery D Evans, Avanafil for treatment of dysfunction: review of its potential, Vasc Health Risk Manag. 2012; 8: 517–523.
  2. DeRogatis LR, Burnett AL. ʻO ka maʻi'ōpilikia o ka moe kolohe. J Sex Med. 2008; 5: 289-300.
  3. Zhao C, Kim S, Yan D, et al. Efficacy and safety of avanafil for treating dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int. 2012 Mar 27;

ʻO Shangke Chemical he polokalamu kelehana kiʻekiʻe e kū nei i nā mea hana hana hoʻopihamaha hana (APIs). No ka mālamaʻana i ka maikaʻi i ka manawa o ka hanaʻana, kahi nui o nāʻoihana akamai, nā mea hana papa hana mua a me nā hale liʻiliʻi i nā kumu nui.

Kāhea iā mā˚ou